Skip to content
Screener

Alto Neuroscience ANRO Price / book

Price / book at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
4.7×+0.8×
LBR
LB Pharmaceuticals IncLBRX
1.9×—
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
174.8×+171×
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
4.7×+3.0×
MapLight Therapeutics, Inc. logo
MapLight Therapeutics, Inc.MPLT
2.2×—
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
3.3×-1.2×

Other financials

Income statement

See full
Operating income-$27.1M-73.1%
Net income-$26.2M-73.0%
EPS (diluted)-$0.80-42.9%

Balance sheet

See full
Cash & equivalents$264.3M+63.9%
Total debt$20.9M-17.2%
Total equity$243.4M+75.0%
Total assets$276.3M+60.7%

Cash flow

See full
Operating cash flow-$27.1M-63.6%
CapEx$556.0K+2,217%
Free cash flow-$27.6M-66.7%

Valuation

See full
Market cap$1.11B+1,245%
Enterprise value$871.03M-2,281%

Returns & leverage

See full
Return on equity-38.9%+0.9pp
Debt / equity0.1×-0.1×
Current ratio20.5×-2.0×

Where this comes from

Calculated from Alto Neuroscience’s reported figures.

market cap/total stockholders equity=3×

Based on the most recent quarter.

The source filing: Alto Neuroscience’s 10-Q, filed May 13, 2026. Open the filing →

Filed
May 13, 2026, 7:30 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001999480-26-000012

FAQ

What is Alto Neuroscience's price / book?
Alto Neuroscience (ANRO) reported price / book of 3× in Q1 2026.
How has Alto Neuroscience's price / book changed year-over-year?
Alto Neuroscience's price / book increased by 601.9% year-over-year, from 0.4× to 3×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

Ask your AI about Alto Neuroscience's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude